EP2827851A4 - Extended-release formulation for reducing the frequency of urination and method of use thereof - Google Patents

Extended-release formulation for reducing the frequency of urination and method of use thereof

Info

Publication number
EP2827851A4
EP2827851A4 EP13763665.0A EP13763665A EP2827851A4 EP 2827851 A4 EP2827851 A4 EP 2827851A4 EP 13763665 A EP13763665 A EP 13763665A EP 2827851 A4 EP2827851 A4 EP 2827851A4
Authority
EP
European Patent Office
Prior art keywords
urination
extended
frequency
reducing
release formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13763665.0A
Other languages
German (de)
French (fr)
Other versions
EP2827851A1 (en
Inventor
David A Dill
Ilya A Volfson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellesley Pharmaceuticals LLC
Original Assignee
Wellesley Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/424,000 external-priority patent/US8236857B2/en
Priority claimed from US13/487,348 external-priority patent/US20120244221A1/en
Application filed by Wellesley Pharmaceuticals LLC filed Critical Wellesley Pharmaceuticals LLC
Publication of EP2827851A1 publication Critical patent/EP2827851A1/en
Publication of EP2827851A4 publication Critical patent/EP2827851A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP13763665.0A 2012-03-19 2013-03-14 Extended-release formulation for reducing the frequency of urination and method of use thereof Withdrawn EP2827851A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/424,000 US8236857B2 (en) 2010-07-08 2012-03-19 Extended-release formulation for reducing the frequency of urination and method of use thereof
US13/487,348 US20120244221A1 (en) 2010-07-08 2012-06-04 Extended-release formulation for reducing the frequency of urination and method of use thereof
PCT/US2013/031617 WO2013142274A1 (en) 2012-03-19 2013-03-14 Extended-release formulation for reducing the frequency of urination and method of use thereof

Publications (2)

Publication Number Publication Date
EP2827851A1 EP2827851A1 (en) 2015-01-28
EP2827851A4 true EP2827851A4 (en) 2015-10-14

Family

ID=49223209

Family Applications (2)

Application Number Title Priority Date Filing Date
EP13763764.1A Withdrawn EP2827852A4 (en) 2012-03-19 2013-03-13 Extended-release formulation for reducing the frequency of urination and method of use thereof
EP13763665.0A Withdrawn EP2827851A4 (en) 2012-03-19 2013-03-14 Extended-release formulation for reducing the frequency of urination and method of use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP13763764.1A Withdrawn EP2827852A4 (en) 2012-03-19 2013-03-13 Extended-release formulation for reducing the frequency of urination and method of use thereof

Country Status (15)

Country Link
EP (2) EP2827852A4 (en)
JP (5) JP2015510928A (en)
KR (4) KR20140134333A (en)
CN (4) CN104302284A (en)
AU (4) AU2013235518B2 (en)
BR (2) BR112014020271A8 (en)
CA (2) CA2866853A1 (en)
HK (3) HK1204553A1 (en)
MX (3) MX2014011128A (en)
MY (2) MY174090A (en)
NZ (6) NZ712594A (en)
RU (3) RU2669565C2 (en)
SG (2) SG11201500408VA (en)
WO (2) WO2013142197A1 (en)
ZA (2) ZA201405862B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10596127B2 (en) 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
JP2016525548A (en) 2013-07-23 2016-08-25 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉ� Methods and compositions comprising desmopressin in combination with Β-3 adrenergic receptor stimulants
WO2015187183A1 (en) * 2014-06-06 2015-12-10 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
KR101809908B1 (en) * 2014-07-21 2018-01-25 주식회사 종근당 Pharmaceutical composition comprising 5-α reductase inhibitor
KR20170097045A (en) * 2014-11-20 2017-08-25 알레간 인코포레이티드 Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist
EP3355864A4 (en) * 2015-09-30 2019-05-22 Wellesley Pharmaceuticals, LLC Composition for reducing the frequency of urination, method of making and use thereof
AU2016331879A1 (en) * 2015-09-30 2018-05-17 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
CN105238124B (en) * 2015-11-16 2018-02-09 太仓东能环保设备有限公司 A kind of antibacterial mastic powder
JP6294924B2 (en) 2016-09-05 2018-03-14 株式会社Ｓｕｂａｒｕ Vehicle travel control device

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1053752A1 (en) * 1998-02-10 2000-11-22 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
WO2001019350A1 (en) * 1999-09-14 2001-03-22 Copley Pharmaceutical Inc. Controlled release formulation for administration of an anti-inflammatory naphthalene derivative
WO2003070233A1 (en) * 2002-02-19 2003-08-28 Pharmacia Corporation Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
US20040054008A1 (en) * 2002-09-13 2004-03-18 Tohru Araki Medicament for treatment of nocturia
US20040198822A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmacueticals, Inc. Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators
EP1552825A1 (en) * 2002-06-07 2005-07-13 Yamanouchi Pharmaceutical Co. Ltd. Therapeutic agent for overactive bladder
EP1627876A1 (en) * 2004-08-20 2006-02-22 Ferring B.V. Heterocyclic condensed compounds useful as antidiuretic agents
US20080085314A1 (en) * 2005-07-29 2008-04-10 Shalaby Shalaby W Solid oral formulations for combination therapy
WO2010138441A1 (en) * 2009-05-28 2010-12-02 Aptapharma, Inc. Multilayer oral tablets containing a non-steroidal anti-inflammatory drug and/or acetaminophen
WO2011107755A2 (en) * 2010-03-05 2011-09-09 University Of Strathclyde Immediate/delayed drug delivery
US20120010294A1 (en) * 2010-07-08 2012-01-12 Dill David A Compositions and methods for the inhibition of muscle contraction

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10116978A1 (en) * 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa opiate agonists for the treatment of diseases of the bladder
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
BR0318201A (en) * 2003-03-21 2006-03-21 Mcneil Ppc Inc non-steroidal anti-inflammatory drug dosage regimen
EP2248524A3 (en) * 2004-08-25 2011-03-09 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
US20070021357A1 (en) * 2005-06-17 2007-01-25 Dynamis Therapeutics, Inc. Treatment of inflammatory conditions
ATE506059T1 (en) * 2005-09-02 2011-05-15 Theravida Inc THERAPY TO TREAT OVERACTIVE BLADDER
US20120244221A1 (en) * 2010-07-08 2012-09-27 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1053752A1 (en) * 1998-02-10 2000-11-22 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
WO2001019350A1 (en) * 1999-09-14 2001-03-22 Copley Pharmaceutical Inc. Controlled release formulation for administration of an anti-inflammatory naphthalene derivative
WO2003070233A1 (en) * 2002-02-19 2003-08-28 Pharmacia Corporation Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
EP1552825A1 (en) * 2002-06-07 2005-07-13 Yamanouchi Pharmaceutical Co. Ltd. Therapeutic agent for overactive bladder
US20040054008A1 (en) * 2002-09-13 2004-03-18 Tohru Araki Medicament for treatment of nocturia
US20040198822A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmacueticals, Inc. Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators
EP1627876A1 (en) * 2004-08-20 2006-02-22 Ferring B.V. Heterocyclic condensed compounds useful as antidiuretic agents
US20080085314A1 (en) * 2005-07-29 2008-04-10 Shalaby Shalaby W Solid oral formulations for combination therapy
WO2010138441A1 (en) * 2009-05-28 2010-12-02 Aptapharma, Inc. Multilayer oral tablets containing a non-steroidal anti-inflammatory drug and/or acetaminophen
WO2011107755A2 (en) * 2010-03-05 2011-09-09 University Of Strathclyde Immediate/delayed drug delivery
US20120010294A1 (en) * 2010-07-08 2012-01-12 Dill David A Compositions and methods for the inhibition of muscle contraction

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ADDLA S K ET AL: "Diclofenac for Treatment of Nocturia Caused by Nocturnal Polyuria: A Prospective, Randomised, Double-Blind, Placebo-Controlled Crossover Study", EUROPEAN UROLOGY, ELSEVIER BV, NL, vol. 49, no. 4, 1 April 2006 (2006-04-01), pages 720 - 726, XP027881854, ISSN: 0302-2838, [retrieved on 20060401] *
JOHNSON ET AL: "Changes in Nocturia From Medical Treatment of Benign Prostatic Hyperplasia: Secondary Analysis of the Department of Veterans Affairs Cooperative Study Trial", JOURNAL OF UROLOGY, LIPPINCOTT WILLIAMS & WILKINS, BALTIMORE, MD, US, vol. 170, no. 1, 1 July 2003 (2003-07-01), pages 145 - 148, XP005536007, ISSN: 0022-5347, DOI: 10.1097/01.JU.0000069827.09120.79 *
MATTHIESEN ET AL: "Nocturnal Polyuria and Natriuresis in Male Patients with Nocturia and Lower Urinary Tract Symptoms", JOURNAL OF UROLOGY, LIPPINCOTT WILLIAMS & WILKINS, BALTIMORE, MD, US, vol. 156, no. 4, 1 October 1996 (1996-10-01), pages 1292 - 1299, XP005573755, ISSN: 0022-5347, DOI: 10.1016/S0022-5347(01)65572-1 *
PINNA C ET AL: "Altered neurogenic and mechanical responses to acetylcholine, ATP and substance P in detrusor from rat with outlet obstruction", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 79, no. 13, 22 August 2006 (2006-08-22), pages 1301 - 1306, XP028051173, ISSN: 0024-3205, [retrieved on 20060822], DOI: 10.1016/J.LFS.2006.03.035 *
See also references of WO2013142274A1 *
SMITH, A. L. AND WEIN, A. J.: "Outcomes of pharmacological management of nocturia with non-antidiuretic agents: does statistically significant equal clinically significant?", BJU INTERNATIONAL, vol. 107, no. 10, 31 May 2011 (2011-05-31), pages 1550 - 1554, XP002743295, DOI: 10.1111/j.1464-410X.2010.09972.x *
WEIN A J ET AL: "Overactive Bladder: A Better Understanding of Pathophysiology, Diagnosis and Management", JOURNAL OF UROLOGY, LIPPINCOTT WILLIAMS & WILKINS, BALTIMORE, MD, US, vol. 175, no. 3, 1 March 2006 (2006-03-01), pages S5 - S10, XP024989968, ISSN: 0022-5347, [retrieved on 20060301], DOI: 10.1016/S0022-5347(05)00313-7 *
WEISS ET AL: "NOCTURIA", JOURNAL OF UROLOGY, LIPPINCOTT WILLIAMS & WILKINS, BALTIMORE, MD, US, vol. 163, no. 1, 1 January 2000 (2000-01-01), pages 5 - 12, XP005556162, ISSN: 0022-5347, DOI: 10.1016/S0022-5347(05)67961-X *

Also Published As

Publication number Publication date
CA2866755A1 (en) 2013-09-26
BR112014020271A8 (en) 2017-07-11
EP2827851A1 (en) 2015-01-28
MX2014011128A (en) 2015-08-10
ZA201405862B (en) 2016-08-31
CN104321056A (en) 2015-01-28
SG11201500409SA (en) 2015-03-30
MX2019008817A (en) 2019-09-26
AU2013235518B2 (en) 2017-03-02
JP2018138602A (en) 2018-09-06
KR20140134333A (en) 2014-11-21
NZ712594A (en) 2016-09-30
BR112014020113A8 (en) 2017-07-11
CN107157991A (en) 2017-09-15
AU2013235507B2 (en) 2017-03-23
NZ718163A (en) 2017-09-29
SG11201500408VA (en) 2015-03-30
EP2827852A4 (en) 2016-03-02
WO2013142274A1 (en) 2013-09-26
JP2015510928A (en) 2015-04-13
NZ628079A (en) 2016-05-27
KR20190003840A (en) 2019-01-09
AU2013235518A1 (en) 2014-09-25
RU2669565C2 (en) 2018-10-12
RU2016133305A (en) 2018-12-10
BR112014020271A2 (en) 2017-06-20
JP2016172752A (en) 2016-09-29
HK1204553A1 (en) 2015-11-27
EP2827852A1 (en) 2015-01-28
KR20140134284A (en) 2014-11-21
HK1243921A1 (en) 2018-07-27
NZ714288A (en) 2016-12-23
CN107789626A (en) 2018-03-13
AU2013235507A1 (en) 2014-08-21
BR112014020113A2 (en) 2017-06-20
RU2599017C2 (en) 2016-10-10
CA2866853A1 (en) 2013-07-26
MX2014011129A (en) 2015-08-10
CN104302284A (en) 2015-01-21
RU2014142066A (en) 2016-05-10
NZ714662A (en) 2016-08-26
RU2014142025A (en) 2016-05-10
AU2017203139A1 (en) 2017-06-01
AU2017203246A1 (en) 2017-06-08
HK1251469A1 (en) 2019-02-01
JP2015510936A (en) 2015-04-13
JP2018024693A (en) 2018-02-15
AU2017203246B2 (en) 2018-10-18
WO2013142197A1 (en) 2013-09-26
RU2016133305A3 (en) 2018-12-10
AU2017203139B2 (en) 2018-07-19
MY175764A (en) 2020-07-08
MY174090A (en) 2020-03-09
KR20170015537A (en) 2017-02-08
ZA201406146B (en) 2016-08-31
AU2013235518A2 (en) 2014-10-09
NZ630471A (en) 2016-04-29

Similar Documents

Publication Publication Date Title
IL274404A (en) Expandable body device and method of use
IL261768B (en) Devices and methods for the treatment of tissue
HK1243921A1 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
IL232715A0 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
HK1200690A1 (en) Expandable body device and method of use
ZA201403762B (en) Delayed-release formulation for reducing the frequency of urination and method of use thereof
RS59200B1 (en) C4-monomethyl triterpenoid derivatives and methods of use thereof
EP2709562A4 (en) Tissue restraining devices and methods of use
EP2613735A4 (en) Devices and methods for the treatment of vascular defects
EP2825242A4 (en) Devices and methods for the treatment of vascular defects
EP2790709A4 (en) Hemostatic agents and methods of use
EP2938289A4 (en) Devices and methods for the treatment of vascular defects
IL261232A (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
ZA201408055B (en) Compositions and methods for the treatment of local pain
HK1249438A1 (en) Delayed release formulation for reducing the frequency of urination and method of use thereof
HK1203395A1 (en) Implantable devices and methods for the evaluation of active agent
HK1248549A1 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
HK1203159A1 (en) Prophylactic agent and or therapeutic agent for stress urinary incontinence
AP3759A (en) Method for preparing phenyloxymethyl-nitro-imidazole derivatives and use of the same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140731

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/00 20060101ALI20150818BHEP

Ipc: A61P 13/10 20060101ALI20150818BHEP

Ipc: A61K 45/06 20060101ALI20150818BHEP

Ipc: A61K 31/192 20060101ALI20150818BHEP

Ipc: A61P 7/12 20060101ALI20150818BHEP

Ipc: A61K 31/616 20060101ALI20150818BHEP

Ipc: A61K 31/405 20060101ALI20150818BHEP

Ipc: A61K 31/167 20060101ALI20150818BHEP

Ipc: A61K 31/12 20060101AFI20150818BHEP

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150916

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20181206

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20210120